Search
Cytokinetics Inc
CYTKAdd to Watchlist
53.690USD
-1.860-3.35%
Close 11-06 16:00（ET）
7.46BMarket Cap
LossP/E TTM
Cytokinetics Inc (CYTK) Stock Price Target & Forecast
Analyst Rating
Based on 22 analysts giving stock ratings to Cytokinetics Inc in the past month.
Buy
4 Strong Buy
16 Buy
2 Hold
0 Sell
0 Strong Sell
Target Price
109.778USD+74.28%
CYTK Analyst Recommendation Trends
In the current month, CYTK has received 16 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. CYTK average Analyst price target in the last month is 109.778.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
4
4
4
4
4
3
3
3
16
16
16
16
15
15
14
14
2
2
2
2
3
3
3
3
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
22
22
22
22
22
21
20
20
CYTK Analyst Rating for Peer Comparison
Updated: Nov 5, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
0
0
27
argenx SE
ARGX
10
14
3
0
0
27
Ionis Pharmaceuticals Inc
IONS
6
16
4
0
0
26
Insmed Inc
INSM
6
18
1
0
0
25
Revolution Medicines Inc
RVMD
10
14
1
0
0
25
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
CRISPR Therapeutics AG
CRSP
4
8
11
0
0
23
Tempus AI Inc
TEM
4
7
11
0
1
23
IQVIA Holdings Inc
IQV
8
13
1
0
0
22
Biontech SE
BNTX
4
12
6
0
0
22
Financial Forecasting
Based on analysts' estimates, CYTK EPS is projected to reach -1.431 in FY2026Q4, following reported EPS of -1.367 in FY2026Q3. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
FY2027Q1
Forecast
-1.65
-1.64
-1.45
-1.43
-1.42
Actual
-1.67
-1.50
-1.37
--
--
Surprise
-1.12%
+8.27%
+6.03%
--
--
FAQs
What is Cytokinetics Inc's expected revenue for the next quarter?
Cytokinetics Inc's expected revenue is 63.31M.
What is Cytokinetics Inc's price target?
Analysts forecast that Cytokinetics Inc's price target is USD 109.61, with the highest forecast at USD 146.00 and the lowest forecast at USD 78.00.
How have Cytokinetics IncCYTK's recent earnings per share performed?
The market expectation was USD -1.37, while Cytokinetics IncCYTK's earnings per share (EPS) for the previous quarter was USD -1.50. EPS for the next quarter is expected at USD -1.43.
What is the analyst rating for Cytokinetics Inc?
Based on the ratings of Cytokinetics Inc's stock from 22 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.